Literature DB >> 20809225

The addition of rituximab to fludarabine and cyclophosphamide improves progression-free survival in patients with previously treated chronic lymphocytic leukemia.

Amit Mahipal1, Mark Weiss.   

Abstract

Entities:  

Year:  2010        PMID： 20809225     DOI： 10.1007/s11912-010-0122-3

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  10 in total

1.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

2.  Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Authors:  Barbara F Eichhorst; Raymonde Busch; Georg Hopfinger; Rita Pasold; Manfred Hensel; Cordelia Steinbrecher; Siegfried Siehl; Ulrich Jäger; Manuela Bergmann; Stephan Stilgenbauer; Carmen Schweighofer; Clemens M Wendtner; Hartmut Döhner; Günter Brittinger; Bertold Emmerich; Michael Hallek
Journal:  Blood       Date:  2005-10-11       Impact factor: 22.113

3.  Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

Authors:  William Wierda; Susan O'Brien; Sijin Wen; Stefan Faderl; Guillermo Garcia-Manero; Deborah Thomas; Kim-Anh Do; Jorge Cortes; Charles Koller; Miloslav Beran; Alessandra Ferrajoli; Francis Giles; Susan Lerner; Maher Albitar; Hagop Kantarjian; Michael Keating
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

4.  Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.

Authors:  Mark A Weiss; Peter G Maslak; Joseph G Jurcic; David A Scheinberg; Timothy B Aliff; Nicole Lamanna; Stanley R Frankel; Steven E Kossman; Denise Horgan
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

5.  Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

Authors:  Tadeusz Robak; Anna Dmoszynska; Philippe Solal-Céligny; Krzysztof Warzocha; Javier Loscertales; John Catalano; Boris V Afanasiev; Loree Larratt; Christian H Geisler; Marco Montillo; Ilya Zyuzgin; Peter S Ganly; Caroline Dartigeas; András Rosta; Jörg Maurer; Myriam Mendila; M Wayne Saville; Nancy Valente; Michael K Wenger; Sergey I Moiseev
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

6.  Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.

Authors:  Kenneth A Foon; Michael Boyiadzis; Stephanie R Land; Stanley Marks; Anastasios Raptis; Louis Pietragallo; Dennis Meisner; Andrew Laman; Mathew Sulecki; Allyson Butchko; Patricia Schaefer; Diana Lenzer; Ahmad Tarhini
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.

Authors:  Barbara F Eichhorst; Raymonde Busch; Stephan Stilgenbauer; Martina Stauch; Manuela A Bergmann; Matthias Ritgen; Nicole Kranzhöfer; Robert Rohrberg; Ulrike Söling; Oswald Burkhard; Anne Westermann; Valentin Goede; Carmen D Schweighofer; Kirsten Fischer; Anna-Maria Fink; Clemens M Wendtner; Günter Brittinger; Hartmut Döhner; Bertold Emmerich; Michael Hallek
Journal:  Blood       Date:  2009-07-15       Impact factor: 22.113

Review 8.  Chronic lymphocytic leukaemia.

Authors:  G Dighiero; T J Hamblin
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

9.  Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

Authors:  Nicole Lamanna; Matt Kalaycio; Peter Maslak; Joseph G Jurcic; Mark Heaney; Renier Brentjens; Andrew D Zelenetz; Denise Horgan; Alison Gencarelli; Katherine S Panageas; David A Scheinberg; Mark A Weiss
Journal:  J Clin Oncol       Date:  2006-03-06       Impact factor: 50.717

10.  Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.

Authors:  Nicole Lamanna; Joseph G Jurcic; Ariela Noy; Peter Maslak; Alison N Gencarelli; Katherine S Panageas; Mark L Heaney; Renier J Brentjens; David W Golde; David A Scheinberg; Andrew D Zelenetz; Mark A Weiss
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 50.717
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.